[go: up one dir, main page]

MX2009003184A - Composiciones farmaceuticas que comprenden nilotinib o su sal. - Google Patents

Composiciones farmaceuticas que comprenden nilotinib o su sal.

Info

Publication number
MX2009003184A
MX2009003184A MX2009003184A MX2009003184A MX2009003184A MX 2009003184 A MX2009003184 A MX 2009003184A MX 2009003184 A MX2009003184 A MX 2009003184A MX 2009003184 A MX2009003184 A MX 2009003184A MX 2009003184 A MX2009003184 A MX 2009003184A
Authority
MX
Mexico
Prior art keywords
salt
nilotinib
pharmaceutical compositions
granules
produced
Prior art date
Application number
MX2009003184A
Other languages
English (en)
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009003184(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009003184A publication Critical patent/MX2009003184A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una composición farmacéutica, en especial cápsulas, la cual comprende gránulos que contienen nilotinib o una sal del mismo, con cuando menos un excipiente farmacéuticamente aceptable. Los gránulos se pueden producir mediante un proceso de granulación húmeda.
MX2009003184A 2006-09-27 2007-09-25 Composiciones farmaceuticas que comprenden nilotinib o su sal. MX2009003184A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (en) 2006-09-27 2006-09-27 Pharmaceutical compositions comprising nilotinib or its salt
PCT/EP2007/060165 WO2008037716A2 (en) 2006-09-27 2007-09-25 Pharmaceutical compositions comprising nilotinib or its salt

Publications (1)

Publication Number Publication Date
MX2009003184A true MX2009003184A (es) 2009-04-03

Family

ID=37684496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003184A MX2009003184A (es) 2006-09-27 2007-09-25 Composiciones farmaceuticas que comprenden nilotinib o su sal.

Country Status (35)

Country Link
US (2) US8293756B2 (es)
EP (4) EP1923053A1 (es)
JP (2) JP5567340B2 (es)
KR (2) KR20090076931A (es)
CN (2) CN104306350A (es)
AR (1) AR062980A1 (es)
AU (1) AU2007301977B2 (es)
BR (1) BRPI0719438B1 (es)
CA (1) CA2662571C (es)
CL (1) CL2007002766A1 (es)
CO (1) CO6160288A2 (es)
CY (2) CY1117021T1 (es)
DK (2) DK3984528T3 (es)
ES (3) ES2556625T5 (es)
FI (2) FI2068839T4 (es)
HK (1) HK1133193A1 (es)
HR (2) HRP20230753T3 (es)
HU (2) HUE028204T2 (es)
IL (1) IL197496A (es)
JO (1) JO3757B1 (es)
LT (1) LT3984528T (es)
MA (1) MA30807B1 (es)
MX (1) MX2009003184A (es)
MY (1) MY148237A (es)
NO (2) NO347404B1 (es)
NZ (1) NZ575317A (es)
PE (2) PE20081379A1 (es)
PL (2) PL3984528T3 (es)
PT (2) PT2068839E (es)
RU (1) RU2469707C2 (es)
SI (2) SI3984528T1 (es)
TN (1) TN2009000093A1 (es)
TW (3) TW201418245A (es)
WO (1) WO2008037716A2 (es)
ZA (1) ZA200901511B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2011036305A2 (en) 2009-09-28 2011-03-31 Medizinische Universität Wien New use of pdgfrbeta inhibitors
KR20120099650A (ko) 2009-10-23 2012-09-11 노파르티스 아게 Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
RU2014120792A (ru) 2011-10-28 2015-12-10 Новартис Аг Способ лечения стромальных опухолей желудочно-кишечного тракта
EP2779995A1 (en) * 2011-11-14 2014-09-24 Novartis AG Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
CN104427986A (zh) 2012-07-11 2015-03-18 诺华股份有限公司 治疗胃肠道基质瘤的方法
EP2988729A1 (en) 2013-04-25 2016-03-02 Sun Pharmaceutical Industries Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
ES2908457T3 (es) 2014-08-11 2022-04-29 Sun Pharmaceutical Ind Ltd Novedosas sales de nilotinib y polimorfos de las mismas
WO2016033304A1 (en) * 2014-08-28 2016-03-03 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
BR112018068784A2 (pt) * 2016-03-17 2019-01-22 Sun Pharmaceutical Ind Ltd método para o tratamento de leucemia
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CA3102381A1 (en) 2018-06-15 2019-12-19 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
KR20230097021A (ko) 2020-09-29 2023-06-30 선전 파마신 컴퍼니 리미티드 약학 조성물
CA3224750A1 (en) 2021-06-19 2022-12-22 Helm Ag Granulate composition comprising nilotinib
WO2023285981A1 (en) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Stable pharmaceutical liquid composition of nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
LU103368B1 (en) 2022-12-29 2024-11-04 Renata Pharmaceuticals Ireland Ltd Pharmaceutical suspension of nilotinib
WO2024194718A1 (en) * 2023-03-22 2024-09-26 Unichem Laboratories Limited A stable pharmaceutical composition and process for preparing thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
ATE530542T1 (de) 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
ZA9710927B (en) * 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
EP1200091B1 (en) 1999-08-03 2008-07-02 Lilly Icos LLC Pharmaceutical composition comprising tadalafil
CA2362816C (en) * 1999-12-08 2007-02-06 Pharmacia Corporation Valdecoxib compositions
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
BR0312445A (pt) * 2002-06-07 2005-05-10 Ranbaxy Lab Ltd Sistemas multiunitários para disponibilização de fármaco de liberação modificada
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ES2379075T3 (es) * 2002-11-26 2012-04-20 Universiteit Gent Proceso y aparato para granulación húmeda continua de material en polvo
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
EP1776102A1 (en) 2004-07-28 2007-04-25 Ranbaxy Laboratories Limited Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
JP4884975B2 (ja) * 2004-10-01 2012-02-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 微粒子含有組成物およびその製造方法
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US20080114001A1 (en) * 2005-01-28 2008-05-15 Manley Paul W Use of Pyrimidylaminobenzamides for the Treatment of Diseases that Respond to Modulation of Tie-2 Kinase Activity
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
MX2009001636A (es) * 2006-08-16 2009-02-23 Novartis Ag Metodo para elaborar dispersiones solidas de compuestos terapeuticos altamente cristalinos.
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt

Also Published As

Publication number Publication date
PE20120626A1 (es) 2012-06-07
EP2068839B2 (en) 2022-10-12
CY1126116T1 (el) 2023-11-15
US8501760B2 (en) 2013-08-06
LT3984528T (lt) 2023-08-10
HK1133193A1 (en) 2010-03-19
DK3984528T3 (da) 2023-07-31
TWI428333B (zh) 2014-03-01
CY1117021T1 (el) 2017-04-05
EP3984528B1 (en) 2023-07-05
ES2556625T3 (es) 2016-01-19
EP3009128A1 (en) 2016-04-20
JP5567340B2 (ja) 2014-08-06
TW201418245A (zh) 2014-05-16
PL2068839T3 (pl) 2016-06-30
PT2068839E (pt) 2015-12-30
MA30807B1 (fr) 2009-10-01
MY148237A (en) 2013-03-29
PL2068839T5 (pl) 2023-01-30
AU2007301977B2 (en) 2011-09-08
IL197496A0 (en) 2009-12-24
EP2068839A2 (en) 2009-06-17
AR062980A1 (es) 2008-12-17
HRP20151383T4 (hr) 2023-03-03
ES2556625T5 (es) 2023-03-02
HUE028204T2 (en) 2016-12-28
BRPI0719438B1 (pt) 2022-04-19
TW201418244A (zh) 2014-05-16
WO2008037716A2 (en) 2008-04-03
NO346639B1 (no) 2022-11-07
NO20091501L (no) 2009-04-24
RU2009115782A (ru) 2010-11-10
CO6160288A2 (es) 2010-05-20
NO20220946A1 (no) 2009-04-24
SI3984528T1 (sl) 2023-09-29
CA2662571C (en) 2016-09-27
TWI540128B (zh) 2016-07-01
HUE063083T2 (hu) 2023-12-28
US8293756B2 (en) 2012-10-23
US20130023549A1 (en) 2013-01-24
ZA200901511B (en) 2010-02-24
FI2068839T4 (fi) 2023-01-31
AU2007301977A1 (en) 2008-04-03
CN101516344A (zh) 2009-08-26
HRP20151383T1 (hr) 2016-01-15
EP1923053A1 (en) 2008-05-21
DK2068839T3 (da) 2016-01-11
CA2662571A1 (en) 2008-04-03
NZ575317A (en) 2011-12-22
JP2010504942A (ja) 2010-02-18
PL3984528T3 (pl) 2023-08-28
HRP20230753T3 (hr) 2023-10-27
JO3757B1 (ar) 2021-01-31
KR20090076931A (ko) 2009-07-13
PE20081379A1 (es) 2008-11-27
TN2009000093A1 (en) 2010-08-19
ES2951547T3 (es) 2023-10-23
EP2068839B1 (en) 2015-09-23
EP3984528A1 (en) 2022-04-20
NO347404B1 (no) 2023-10-16
ES2957912T3 (es) 2024-01-29
US20100087463A1 (en) 2010-04-08
FI3984528T3 (fi) 2023-07-27
TW200821298A (en) 2008-05-16
CL2007002766A1 (es) 2008-08-08
PT3984528T (pt) 2023-08-07
KR101598747B1 (ko) 2016-03-02
BRPI0719438A2 (pt) 2013-12-10
EP3009128B1 (en) 2023-07-05
KR20140121903A (ko) 2014-10-16
CN104306350A (zh) 2015-01-28
WO2008037716A3 (en) 2008-07-17
IL197496A (en) 2016-04-21
JP2014065715A (ja) 2014-04-17
SI2068839T2 (sl) 2023-01-31
RU2469707C2 (ru) 2012-12-20
SI2068839T1 (sl) 2016-02-29

Similar Documents

Publication Publication Date Title
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
AP2384A (en) 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them.
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
EP2201011A4 (en) NEW COMPOUNDS WITH INDAZOUS OUTS, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
WO2006134021A3 (en) Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
HK1096386A1 (en) Indanyl-piperazine compounds, a process for their preparation and pharmaceutical compositions containing them
WO2009022327A3 (en) Novel process for preparing highly pure levocetirizine and salts thereof
UA94624C2 (uk) Арипіпразолу геміфумарат і спосіб його одержання
ZA200603810B (en) Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
ZA200902414B (en) Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HK1126190A1 (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
WO2009133455A3 (en) Pharmaceutical composition of clodipogrel
HK1096097A1 (en) Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200809206B (en) Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled by precipitation and pharmaceutical formulations containing same
IL192963A0 (en) Rimonabant monohydrate, process for the preparation thereof and pharmaceutical compositions containing same
ZA200902413B (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
ZA200805656B (en) Prodrug ER²-selective substances, methods for the production thereof and pharmaceutical compositions containing said compounds
WO2007093168A3 (de) Schnell freisetzende irbesartan-haltige pharmazeutische zusammensetzung
ZA200606276B (en) Polysubstituted 1,1-pyridylaminocyclopropanamine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200606277B (en) Polysubstituted 1,1-pyridyloxycyclopropanamine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200800833B (en) New 1H-indole-pyridinecarboxamide and 1H-indolepiperidinecarboxamide compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200706710B (en) 6-Phenylhex-5-enoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof
WO2008035172A3 (en) Pharmaceutical compositions containing desmopressin

Legal Events

Date Code Title Description
FG Grant or registration